Skip to main content Accessibility help
×
×
Home

Depression and schizophrenia

  • David Castle and Peter Bosanac

Summary

Depressive symptoms commonly occur in schizophrenia and have a significant impact on the distress and burden of the illness. Yet they are often overlooked, inadequately characterised by current classification systems and not consistently integrated into treatment. We discuss nosology, practical and clinical implications of symptom differentiation, and the role of causal and confounding factors, including iatrogenic, as targets for therapeutic intervention. The evidence base of psychosocial and psychotropic management is reviewed, with recommendations for the treatment of established syndromal depression in people with schizophrenia.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Depression and schizophrenia
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Depression and schizophrenia
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Depression and schizophrenia
      Available formats
      ×

Copyright

Corresponding author

Professor David Castle, The University of Melbourne, Level 2, 46 Nicholson Street, Fitzroy, Victoria 3065, Australia. Email: david.castle@svhm.org.au

Footnotes

Hide All

Declaration of Interest

D.C. has received: grant monies from Eli Lilly, Janssen-Cilag, Roche, Allergen, Bristol-Myers Squibb, Pfizer, Lundbeck, AstraZeneca and Hospira; travel support and honoraria for talks and consultancy from Eli Lilly, Bristol-Myers Squibb, AstraZeneca, Lundbeck, Janssen-Cilag, Pfizer, Organon, Sanofi-Aventis, Wyeth and Hospira; and is an advisory board member for Lundbeck, Eli Lilly, Bristol-Myers Squibb, AstraZeneca, Wyeth, Pfizer and Janssen-Cilag, and in the past for Schering Plough. P.B. has received financial support for investigator-initiated studies from AstraZeneca, and travel support from AstraZeneca, Eli Lilly and Janssen-Cilag.

For a brief overview on this illness see Castle DJ (2012) Schizoaffective disorder, 18: 32–33. Ed.

Footnotes

References

Hide All
Addington, D, Addington, J, Schissel, B (1990) A depression rating scale for schizophrenics. Schizophrenia Research 3: 247–51.
Addington, DE, Mohamed, S, Rosenheck, RA et al (2011) Impact of second generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. Journal of Clinical Psychiatry 72: 7580.
Alfredsson, G, Harnryd, C, Wiesel, FA (1984) Effects of sulpiride and chlorpromazine on depressive symptoms in schizophrenic patients – relationship to drug concentrations. Psychopharmacology 84: 237–41.
American Psychiatric Association (1980) Diagnostic and Statistical Manual of Mental Disorders (3rd edn) (DSM-III). APA.
American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM-III-R). APA.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). APA.
American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM-IV-TR). APA.
Arbaizar, B, Dierssen-Sotos, T, Gomez-Acebo, I et al (2009) Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials. General Hospital Psychiatry 31: 478–83.
Barrett, EA, Sundet, K, Faerden, A et al (2010) Suicidality before and in the early phases of psychosis. Schizophrenia Research 119: 11–7.
Berman, RM, Fava, M, Thase, ME et al (2009) Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectrums 14: 197206.
Calabrese, JR, Keck, PE, Macfadden, W et al (2005) A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. American Journal of Psychiatry 162: 1351–60.
Carpenter, WT Jr, Heinrichs, DW, Wagman, AMI (1988) Deficit and nondeficit forms of schizophrenia: the concept. American Journal of Psychiatry 145: 578–83.
Ceskova, E, Svestka, J (1993) Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 26: 121–4.
Cooper, SJ, Mulholland, C, Lynch, G et al (2000) Sertraline in the treatment of depressive symptoms in stable, chronic schizophrenia: a placebo controlled study. Schizophrenia Research 41: 209.
Cutler, AJ, Montgomery, SA, Feifel, D et al (2009) Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. Journal of Clinical Psychiatry 70: 526–39.
Daniel, DG, Zimbroff, D, Potkin, SG et al (1999) Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20: 491505.
Dannlowski, U, Baune, BT, Böckermann, I et al (2008) Adjunctive antidepressant treatment with quetiapine in agitated depression: positive effects on symptom reduction, psychopathology and remission rates. Human Psychopharmacology 23: 587–93.
Dixon, L, Haas, G, Weiden, PJ et al (1991) Drug abuse in schizophrenic patients: clinical correlates and reasons for use. American Journal of Psychiatry 148: 224–30.
Dollfus, S, Olivier, V, Chabot, B et al (2005) Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients. Schizophrenia Research 78: 157–9.
Emsley, RA, Buckley, P, Jones, AM et al (2003) Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. Journal of Psychopharmacology 17: 210–5.
Essali, A, Al-Haj, HN, Li, C et al (2009) Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews 1: CD000059.
Faraone, SV, Blehar, M, Pepple, J et al (1996) Diagnostic accuracy and confusability analyses: an application to the Diagnostic Interview for Genetic Studies. Psychological Medicine 26: 401–10.
Furtado, VA, Srihari, V, Kumar, A (2008) Atypical antipsychotics for people with both schizophrenia and depression. Cochrane Database of Systematic Reviews 1: CD005377.
Glick, ID, Pham, D, Davis, JM (2006) Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia. Journal of Clinical Psychiatry 67: 1261–5.
Glick, ID, Siris, SG, Davis, JM (2008) Treating schizophrenia with comorbid depressive or demoralization symptoms. Journal of Clinical Psychiatry 69: 501.
Goff, DC, Brotman, AW, Waites, M et al (1990) Trial of fluoexetine added to neuroleptics for treatment-resistant schizophrenic patients. American Journal of Psychiatry 147: 492–4.
International Early Psychosis Association Writing Group (2005) The international clinical practice guidelines for early psychosis. British Journal of Psychiatry 187 (suppl 48): s1204.
Jasovic-Gasic, M, Crnobaric, C, Miljevic, C (1997) Antidepressants versus clozapine in the treatment of depressive syndrome in schizophrenia. European Neuropsychopharmacology S2: 272.
Kasanin, J (1933) The acute schizoaffective psychoses. American Journal of Psychiatry 90: 97126.
Kasper, S (2004) Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depression and Anxiety 20: 44–7.
Keck, P, Buffenstein, A, Ferguson, J et al (1998) Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 140: 173–84.
Kemp, DE, Gilmer, WS, Fleck, J et al (2007) Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 31: 574–7.
Kim, SW, Shin, IS, Kim, JM et al (2007) Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. Progress in Neuro-psychopharmacology and Biological Psychiatry 31: 1504–9.
Kim, SW, Shin, IS, Kim, JM et al (2010) Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia. Clinical Neuropharmacology 33: 121–5.
Kinon, BJ, Lipkovich, I, Edwards, B et al (2006) A 24 week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. Journal of Clinical Psychopharmacology 26: 157–62.
Kirkpatrick, B, Buchanan, RW, McKenney, PD et al (1989) The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Research 30: 119–23.
Kopala, LC, Good, KP, Milliken, H et al (2006) Treatment of a first episode of psychotic illness with quetiapine: an analysis of 2 year outcomes. Schizophrenia Research 81: 2939.
Kramer, MS, Vogel, WH, Di Johnson, C et al (1989) Antidepressants in ‘depressed’ schizophrenic inpatients: a controlled trial. Archives of General Psychiatry 46: 922–8.
Lee, KU, Jeon, YW, Lee, HK et al (2009) Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia. Human Psychopharmacology 24: 447–52.
Lewander, T (1994) Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatrica Scandinavica 89 (suppl 380): 813.
Lybrand, J, Caroff, S (2009) Management of schizophrenia with substance use disorders. Psychiatric Clinics of North America 32: 821–33.
Margolese, H, Malchy, S, Negrete, JC et al (2004) Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophrenia Research 67: 157–66.
Mauri, MC, Moliterno, D, Rossattini, M et al (2008) Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugs. Schizophrenia Research 99: 712.
McIntyre, RS, Muzina, DJ, Adams, A et al (2009) Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. Expert Opinion on Pharmacotherapy 10: 3061–75.
Meltzer, HY, Okayli, G (1995) Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. American Journal of Psychiatry 152: 183–90.
Meltzer, HY, Alphs, L, Green, AI et al (2003) Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry 60: 8291.
Möller, HJ, Muller, H, Borison, RL et al (1995) A path analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a re-evaluation of the North American risperidone study. European Archives of Psychiatry and Clinical Neuroscience 245: 45–9.
Papakostas, GI, Petersen, TJ, Kinrys, G et al (2005) Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. Journal of Clinical Psychiatry 66: 1326–30.
Patkar, AA, Peindl, K, Mago, R et al (2006) An open-label, rate-blinded, augmentation study of aripiprazole in treatment-resistant depression. Primary Care Companion to the Journal of Clinical Psychiatry 8: 82–7.
Peuskens, J (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. British Journal of Psychiatry 166: 712–26.
Peuskens, J, Möller, HJ, Puech, A (2002) Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. European Neuropsychopharmacology 12: 305–10.
Pilling, S, Bebbington, P, Kuipers, E et al (2002) Psychological treatments in schizophrenia. I: Meta-analysis of family interventions and cognitive behaviour therapy. Psychological Medicine 32: 763–82.
Prusoff, BA, Williams, DH, Weismann, MM et al (1979) Treatment of secondary depression in schizophrenia. Archives of General Psychiatry 36: 569–75.
Rutherford, B, Sneed, J, Miyazaki, M et al (2007) An open-label trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. International Journal of Geriatric Psychiatry 22: 986–91.
Schwartz, TL, Nasra, GS, Chilton, M et al (2007) Aripiprazole augmentation of selective serotonin reuptake inhibitors in the treatment of major depressive disorder. Primary Psychiatry 14: 67–9.
Siris, SG (2000) Depression in schizophrenia: perspective in the era of ‘atypical’ antipsychotic agents. American Journal of Psychiatry 157: 1379–89.
Siris, SG, Bench, C (2003) Depression and schizophrenia. In Schizophrenia (2nd edn) (eds Hirsch, S, Weinberger, D) 142–67. Blackwell.
Siris, SG, Bermanzohn, PC, Mason, SE et al (1994) Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial. Archives of General Psychiatry 51: 109–15.
Sokolski, KN (2007) Adjunctive aripiprazole in bipolar I depression. Annals of Pharmacotherapy 41: 3540.
Steffens, DC, Nelson, C, Eudicone, JM et al (2011) Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. International Journal of Geriatric Psychiatry 26: 564–72.
Storosum, JG, Elferink, AJA, van Zwieten, BJ et al (2002) Amisulpride: is there a treatment for negative symptoms in schizophrenia patients? Schizophrenia Bulletin 28: 193201.
Suppes, T, Datto, C, Minkwitz, M (2009) Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. Journal of Affective Disorders 121: 106–15.
Thase, W, Macfadden, RH, Weisler, W et al (2006) Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). Journal of Clinical Psychopharmacology 26: 600–9.
Tohen, M, Vieta, E, Calabrese, J et al (2003) Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Archives of General Psychiatry 60: 1079–88.
Tollefson, GD, Beasley, CM Jr, Tran, PV et al (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry 154: 457–65.
Tollefson, GD, Sanger, TM, Beasley, CM et al (1998) A double-blind controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biological Psychiatry 43: 803–10.
Tran, PV, Hamilton, SH, Kuntz, AJ et al (1997) Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology 17: 407–8.
Upthegrove, R (2009) Depression in schizophrenia and early psychosis: implications for assessment and treatment. Advances in Psychiatric Treatment 15: 372–9.
Upthegrove, R, Birchwood, M, Ross, K et al (2010) The evolution of depression and suicidality in first episode psychosis. Acta Psychiatrica Scandinavica 122: 211–8.
Vieta, E, Locklear, J, Gunter, O et al (2010) Treatment options for bipolar depression: a systematic review of randomized, controlled trials. Journal of Clinical Psychopharmacology 30: 579–90.
Walker, AM, Lanza, LL, Arellano, F et al (1997) Mortality in current and former users of clozapine. Epidemiology 8: 671–7.
Weisler, R, Joyce, M, McGill, L et al (2009) Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectrums 14: 299313.
World Health Organization (1992) The ICD-10 Classification of mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO.
Zisook, S, Kasckow, JW, Lanouette, NM et al (2010) Augmentation with citalopram for suicidal ideation in middle-aged or older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomised control trial. Journal of Clinical Psychiatry 71: 915–22.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Advances
  • ISSN: 1355-5146
  • EISSN: 1472-1481
  • URL: /core/journals/bjpsych-advances
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Depression and schizophrenia

  • David Castle and Peter Bosanac
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *